IN8bio, Inc. Presents New Preclinical Data on INB-619 at ACR Meeting

On October 27, 2025, IN8bio, Inc. announced new preclinical data for its INB-619 program at the ACR Convergence Meeting.

Key Highlights:

• INB-619 shows efficacy comparable to FDA-approved TCEs with minimal cytokine release.
• First pan-γδ T cell engager to expand multiple γδ T cell subsets for target elimination.
• Achieved complete B cell depletion in both healthy and SLE donor samples.
• Potential for higher doses and deeper B cell depletion with improved safety profile.
• Targets γδ TCR, reducing toxicities associated with conventional TCEs.

Original SEC Filing: IN8BIO, INC. [ INAB ] - 8-K - Oct. 27, 2025